Immunotherapy in Nonmelanoma Skin Cancers

Panelists discuss the current prevalence and treatment landscape of cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC).

Leading experts discuss the evolving role of immunotherapy and neoadjuvant therapies in cSCC and BCC treatment.

Experts explore the optimal sequencing of immunotherapy relative to radiation therapy in CSCC and BCC care.

Key opinion leaders underscore the importance of a multidisciplinary approach that can break down barriers and advance CSCC and BCC therapy.

The panel emphasizes the role of multidisciplinary tumor boards in optimizing oncology care in nonmelanoma skin cancers.

Medical professionals discuss strategies and best practices for recognizing and mitigating immunotherapy toxicities through multidisciplinary collaboration and use of monitoring technology.

Dr Pisano shares insights on expanding dermatologists' comfort with immunotherapy through collaborative learning and collective expertise.

Key opinion leaders emphasize the role of coordinated care between dermatologists and oncologists in monitoring and managing adverse events related to immunotherapy in CSCC and BCC.

Experts discuss optimal utilization of CSCC and BCC staging systems and risk stratification to guide treatment decisions and the appropriate timing for active surveillance vs intervention.

The panel examine toxicity and morbidity considerations for the use of hedgehog pathway inhibitors in BCC.

Experts explore the socioeconomic impact of CSCC and BCC, and which late-stage patients will derive the greatest benefit from hedgehog inhibitors, immunotherapies, and other emerging treatments.

Medical professionals explore CSCC and BCC treatment in high-risk, immunocompromised patients—specifically in the setting of organ transplantation.

Exploring recent trials and updates in nonmelanoma skin cancer treatment.

The panel provides closing thoughts on the future of the CSCC and BCC treatment landscape.